Sutimlimab is generally well tolerated, and the frequency and nature of treatment-emergent adverse events are consistent with those observed in elderly, medically complex patients, according to an analysis of data from two phase 3 studies. Cold agglutinin disease (CAD) is characterized by autoimmune hemolytic anemia mediated by the classical complement pathway. Sutimlimab, a monoclonal humanized...